Zoetis (NYSE:ZTS) had its price objective boosted by BMO Capital Markets to $78.00 in a report issued on Tuesday morning. BMO Capital Markets currently has a market perform rating on the stock.
Several other research analysts also recently commented on ZTS. Zacks Investment Research downgraded Zoetis from a buy rating to a hold rating in a report on Saturday. Cantor Fitzgerald set a $85.00 price objective on Zoetis and gave the stock a buy rating in a report on Tuesday, December 26th. Citigroup upgraded Zoetis from a neutral rating to a buy rating and set a $85.00 price objective on the stock in a report on Thursday, January 4th. Craig Hallum reiterated a buy rating and issued a $85.00 price objective (up previously from $77.00) on shares of Zoetis in a report on Tuesday, January 2nd. Finally, Morgan Stanley upgraded Zoetis from an equal weight rating to an overweight rating and set a $80.00 price objective on the stock in a report on Wednesday, November 29th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. Zoetis presently has a consensus rating of Buy and a consensus price target of $71.28.
Zoetis (NYSE ZTS) traded down $1.20 during midday trading on Tuesday, reaching $73.91. The company’s stock had a trading volume of 2,257,200 shares, compared to its average volume of 2,539,257. Zoetis has a twelve month low of $52.00 and a twelve month high of $75.47. The company has a quick ratio of 1.95, a current ratio of 2.80 and a debt-to-equity ratio of 2.45. The stock has a market capitalization of $36,020.00, a P/E ratio of 38.90, a price-to-earnings-growth ratio of 1.91 and a beta of 1.06.
Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, November 2nd. The company reported $0.65 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.63 by $0.02. Zoetis had a return on equity of 62.39% and a net margin of 18.29%. The business had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.32 billion. During the same quarter last year, the business posted $0.52 earnings per share. The company’s revenue for the quarter was up 8.5% on a year-over-year basis. analysts expect that Zoetis will post 2.37 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, January 19th will be given a dividend of $0.126 per share. This represents a $0.50 annualized dividend and a yield of 0.68%. This is a boost from Zoetis’s previous quarterly dividend of $0.11. The ex-dividend date is Thursday, January 18th. Zoetis’s payout ratio is presently 22.11%.
A number of institutional investors have recently bought and sold shares of the business. BlackRock Inc. boosted its position in Zoetis by 3.9% during the 2nd quarter. BlackRock Inc. now owns 37,495,299 shares of the company’s stock valued at $2,338,957,000 after acquiring an additional 1,412,829 shares in the last quarter. Vanguard Group Inc. boosted its position in Zoetis by 2.8% during the 2nd quarter. Vanguard Group Inc. now owns 33,654,686 shares of the company’s stock valued at $2,099,379,000 after acquiring an additional 910,265 shares in the last quarter. Janus Henderson Group PLC boosted its position in Zoetis by 1.5% during the 3rd quarter. Janus Henderson Group PLC now owns 5,893,853 shares of the company’s stock valued at $375,792,000 after acquiring an additional 84,767 shares in the last quarter. Northern Trust Corp boosted its position in Zoetis by 1.2% during the 2nd quarter. Northern Trust Corp now owns 5,533,313 shares of the company’s stock valued at $345,168,000 after acquiring an additional 63,849 shares in the last quarter. Finally, Legal & General Group Plc boosted its position in shares of Zoetis by 1.5% in the 3rd quarter. Legal & General Group Plc now owns 2,400,106 shares of the company’s stock worth $153,025,000 after purchasing an additional 34,747 shares in the last quarter. 93.19% of the stock is currently owned by institutional investors and hedge funds.
WARNING: This piece of content was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/10/zoetis-zts-price-target-increased-to-78-00-by-analysts-at-bmo-capital-markets.html.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.